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18F-FDG uptake in malignant tumors largely depends on the
presence of facilitated glucose transporters, especially type 1
(Glut 1) and a rate-limiting glycolytic enzyme, hexokinase (HK)
type II. Low expression of Glut 1 was reported in hepatocellular
carcinoma (HCC), whereas high expression was found in chol-
angiocarcinoma. Immunohistochemistry and proteome analysis
were performed to obtain a detailed evaluation of the mecha-
nisms involved in glucose uptake and use in these tumors.
Methods: Tumor tissues obtained from both HCC (n  7) and
mass-forming cholangiocarcinoma patients (n 7) who showed
increased 18F-FDG uptake on PET were used. Immunohisto-
chemistry for Glut 1 and HK I–III was performed in all tumor
tissues. To identify proteins that regulate carbohydrate metab-
olism, a proteome analysis with matrix-assisted laser desorp-
tion ionization–time of flight and enzymatic digestion in-gel were
performed using 8 available tumor samples and 3 normal liver
tissues. Of the 8 tumor samples, 4 were HCCs; one was an
intermediate phenotype HCC, and 3 were cholangiocarcino-
mas. The spot intensity of the proteins was calculated using
proteome data; the tissues then were divided into 2 groups on
the basis of the protein expression pattern, because the protein
expression pattern of the intermediate-phenotype HCC was
close to that of the cholangiocarcinomas. Group A included the
HCCs and group B included the intermediate-phenotype HCC
as well as the cholangiocarcinomas. Results: Immunoreactivity
for Glut 1 was positive in all cholangiocarcinomas, but was
negative in all HCCs except the one intermediate phenotype.
However, HK II was positive in HCCs but was negative in 6 of
the 7 cholangiocarcinomas. A total of 331 protein spots with a
P value of 0.05 were identified by proteome analysis. Thirteen
of these proteins that regulate carbohydrate metabolism were
selected. The pentose phosphate pathway was increased in
both groups, but more significantly in group B. Gluconeogene-
sis enzymes were decreased in both groups, but the tricarbox-
ylic acid cycle–regulating enzyme expression was variable.
Conclusion: HCCs have different glucose-regulating mecha-
nisms from those of cholangiocarcinomas, even though both
tumors showed increased 18F-FDG uptake on PET scans. Fur-
ther studies are required with regard to energy metabolism and
18F-FDG uptake patterns in association with various oncogenic
alterations regulating multiple steps of the glycolytic pathways.
Key Words: 18F-FDG; glucose metabolism; hepatocellular car-
cinoma; cholangiocarcinoma
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In past years, 18F-FDG PET has been widely used clini-
cally in the field of oncology because of its high sensitivity
and specificity, and it also has significant potential for
assessing therapy response (1). Because cancer cell growth
is heavily dependent on glucose metabolism as a major
energy substrate, the 18F-FDG uptake pattern on PET scans
that reflects glycolytic activity could be an indicator of the
prognosis and aggressiveness of the tumors. In addition, the
association of neoplastic growth with increased aerobic
glycolysis has been known as the Warburg effect for more
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than 7 decades (2). However, 18F-FDG uptake patterns in
primary hepatic tumors are variable. Increased uptake can
be seen in only half of hepatocellular carcinoma (HCC)
patients (3); mass-forming intrahepatic cholangiocarcino-
mas show intense 18F-FDG uptake, whereas hilar cholan-
giocarcinomas show only mild uptake (4).
In our previous study, the 18F-FDG uptake was closely
correlated with the pathologic grading in HCC. HCCs with
increased 18F-FDG uptake showed molecular features of
more aggressive biologic properties than those with a low
18F-FDG uptake (5). However, the glucose uptake pattern
and its clinical implications have not been evaluated in
cholangiocarcinomas.
18F-FDG uptake in malignant tumors depends largely on
the presence of facilitated glucose transporters, including
type 1 (Glut 1) and a rate-limiting glycolytic enzyme, hexo-
kinase (HK) type II (6). In previous reports, it was demon-
strated that Glut 1 is highly expressed in cholangiocarcino-
mas but rarely expressed in HCCs (7,8). In contrast, HK II
expression is increased in HCCs (9) but unknown in cholan-
giocarcinomas. These findings suggest that glucose uptake
and glycolytic mechanisms could differ between HCCs and
cholangiocarcinomas, even though both tumors use glucose
as a major energy source. To explore the differences of
mechanisms involving glucose uptake and glycolysis in
these tumors, immunohistochemistries for Glut 1 and HK
I–III were performed as well as proteome analysis of the
enzymes regulating the glucose metabolism using the tumor
tissues obtained from HCC and mass-forming cholangiocar-




Tumor tissue specimens from 14 patients (7 HCCs and 7
cholangiocarcinomas) who had undergone partial hepatectomy
were obtained and stored in a deep freezer (70°C) for proteomic
analysis or embedded in paraffin for hematoxylin–eosin staining
and immunohistochemistry. The age of the patients ranged from 40
to 73 y. All tumor tissues demonstrated increased 18F-FDG uptake
on a PET scan (standardized uptake values [SUVs] of 18F-FDG
ranged from 3.2 to 17.4). Approval was obtained from the Ethical
Committee in our institute for this study.
PET Procedure
Before surgery, all patients were examined with a whole-body
PET camera (Advance; GE Healthcare). Before scanning, patients
fasted for at least 6 h, and their plasma glucose concentrations
were measured. The blood glucose level was 140 mg/dL. Ap-
proximately 370 MBq 18F-FDG were injected intravenously, and
the emission scan (5 min/bed) was started from the neck to the
knee in 2-dimensional (2D) mode 50–60 min after the injection.
Patients then underwent a transmission scan (3 min/bed) with
rotating 68Ge sources. The images were reconstructed with the
attenuation-corrected ordered-subset expectation maximization al-
gorithm (number of subsets, 16; number of iterations, 2). The PET
scans were compared with the corresponding CT or MR images for
an accurate localization of the tumors. The coronal, sagittal, and
axial images of the patients were qualitatively evaluated to deter-
mine whether the 18F-FDG uptake in the tumor was higher than
that in the surrounding noncancerous hepatic tissue. For a semi-
quantitative evaluation, a small region of interest (8 pixels) was
placed over the area of maximum 18F-FDG uptake in the tumors
and the maximum SUV (SUVmax) normalized to body weight was
calculated.
Immunohistochemistry
Hematoxylin–eosin staining of 5-m-thick paraffin sections
was performed and sections were then deparaffinized and rehy-
drated for immunohistochemistry. After wax removal and dehy-
dration, sections were pretreated in a 0.01 mol/L citrate buffer (pH
6.0) using a microwave oven (820 W, 15 min) for antigen retrieval.
They were then incubated with primary antibodies at 4°C over-
night. These primary antibodies were polyclonal human anti-Glut
1, rat antihexokinase type II, monoclonal anti-HK type I and type
III (Chemicon International Inc.), and monoclonal anticytokeratin
(CK)-19 (Dako). The antibodies were diluted to 1:1,000, 1:5,000,
1:100, 1:200, and 1:50, respectively. Endogenous peroxidase ac-
tivity was blocked by incubation in H2O2 for 10 min. After
washing, signals were detected using an EnVision Kit (Dako) and
diaminobenzidine. The presence of membrane-bound Glut 1 and
intracytoplasmic HK I–III was examined for all tumor tissues, and
CK-19 was evaluated in HCCs for further classification of HCCs
into a primary HCC and an intermediate (hepatocyte-cholangio-
cyte) phenotype (10). Sections incubated with preimmune serum
served as negative controls. Red blood cells present in the tissues
and rat skeletal muscle served as positive controls for Glut 1 and
hexokinases, respectively,
Proteome Analysis
An adequate amount of protein was obtained from 8 tumor
specimens (5 HCCs and 3 cholangiocarcinomas) and 3 adjacent
normal tissues. Proteome analysis was undertaken using these
samples.
Reagents. Urea, thiourea, 3-([3-cholamidopropy]dimethyammo-
nio)-1-propanesulfonate (CHAPS), dithiothreitol (DTT), benzami-
dine, Bradford solution, acrylamide, iodoacetamide, bisacrylam-
ide, sodium dodecylsulfate (SDS), acetonitrile, trifluoroacetic acid,
and -cyano-4-hydroxycinnamic acid were purchased from Sig-
ma-Aldrich. Pharmalyte (pH 3.5–10) was from Amersham Bio-
sciences and immobilized pH gradient (IPG) DryStrips (pH 4–10;
nonlinear, 24 cm) were from Genomine Inc. Modified porcine
trypsin (sequencing grade) was from Promega.
Protein Sample Preparation. Tissue samples were washed twice
in ice-cold phosphate-buffered saline, blotted to dry, and directly
homogenated using a motor-driven homogenizer (Fisher Scien-
tific) with a sample buffer containing 7 mol/L urea, 2 mol/L
thiourea (containing 4% [w/v] CHAPS, 1% [w/v] DTT, and 2%
[v/v] pharmalyte), and 1 mmol/L benzamidine. Proteins were
extracted for 1 h at room temperature. After being centrifuged at
15,000g for 1 h at 15°C, the insoluble material was discarded and
the soluble fraction was used for a 2D gel electrophoresis. In
addition, a membrane fraction was obtained after centrifuging the
sample at 1,400g. Protein loading was normalized using a Brad-
ford Assay (11).
2D Polyacrylamide Gel Electrophoresis (PAGE). IPG dry strips
were equilibrated for 12–16 h with sample buffer containing 7
mol/L urea and 2 mol/L thiourea (containing 2% CHAPS, 1%
DTT, and 1% pharmalyte) and loaded with 200 g of sample.
Isoelectric focusing (IEF) was performed at 20°C using a Mul-
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tiphor II electrophoresis unit and an EPS 3500 XL power supply
(Amersham Biosciences) following the manufacturer’s instruc-
tions. For IEF, the voltage was increased linearly from 150 to
3,500 V for 3 h to allow for sample entry. This was followed by a
constant 3,500 V, with focusing complete after 96 kVh. Before the
second dimension, strips were incubated for 10 min in an equili-
bration buffer (50 mmol/L Tris-Cl, pH 6.8, containing 6 mol/L
urea, 2% SDS, and 30% glycerol), first with 1% DTT and then
with 2.5% iodoacetamide. The equilibrated strips were inserted
into SDS–PAGE gels (20–24 cm, 10%–16%). SDS–PAGE was
performed using the Hoefer DALT 2D system (Amersham Bio-
sciences) following the manufacturer’s instructions. Two-dimen-
sional gels were run at 20°C for 1.7 kVh and then silver stained as
described by Oakley et al. (12).
Image Analysis. A quantitative analysis of digitized images was
performed using PDQuest software, version 7.0 (BioRad). The
quantity of each spot was normalized by total valid spot intensity.
Enzymatic Digestion of Protein In-Gel. Protein spots were di-
gested in-gel using modified porcine trypsin in a manner similar to
that previously described by Shevchenko et al. (13). The gel pieces
were washed with 50% acetonitrile to remove any remaining SDS,
salt, and stain, Next, the pieces were dried to remove any solvent,
then rehydrated with trypsin (8–10 ng/L) and incubated for 8–10
h at 37°C. The proteolytic reaction was terminated by the addition
of 5 L 0.5% trifluoroacetic acid. Peptides were recovered by
combining the aqueous phases obtained from extracting pieces of
gel with 50% aqueous acetonitrile. After concentration, the peptide
mixture was desalted using C18ZipTips (Millipore) and eluted in
1–5 L of acetonitrile. An aliquot of this solution was mixed with
an equal volume of a saturated solution of -cyano-4-hydroxycin-
namic acid in 50% aqueous acetonitrile, and 1 L of the mixture
was spotted onto a target plate.
Matrix-Assisted Laser Desorption Ionization–Time-of-Flight
(MALDI–TOF) Analysis and Database Search. A protein analysis
was performed using MALDI–TOF (Amersham Biosciences).
Peptides were evaporated with an N2 laser at 337 nm using a
delayed extraction approach. They were accelerated with a 20-kV
injection pulse to analyze the time of flight. Each spectrum was the
cumulative average of 300 laser shots. The search program Pro-
Found, developed by Rockefeller University (http://129.85.19.192/
profound_bin/WebProFound.exe), was used for protein identifica-
tion using peptide mass fingerprinting. Spectra were calibrated
with the trypsin autodigestion ion peaks m/z (842.510, 2211.1046)
as internal standards.
Data Analysis. Tumor specimens were divided into 2 groups on
the basis of their protein expression patterns. HCCs were part of
group A, whereas group B included the intermediate-phenotype
HCC and the cholangiocarcinomas, because the protein expression
pattern of the intermediate-phenotype HCC was close to that of the
cholangiocarcinoma group (Figs. 1A and 1B). Comparisons be-
tween the 2 characteristics (normal vs. group A, normal vs. group
B, and group A vs. group B) were assessed using a Student t test,
and relationships were considered statistically significant when
P  0.05. Relative spot intensity (tumor/normal) was calculated in
each group for comparison.
Reverse Transcription–Polymerase Chain Reaction
(RT–PCR)
Total RNA was successfully isolated from 2 HCCs including
the intermediate phenotype, 2 cholangiocarcinomas, and 3 adja-
cent normal liver tissues using a Trizol reagent (Introgen) as
directed by the manufacturer’s protocol. Messenger RNA (mRNA)
expression of the first reaction enzyme in the pentose phosphate
pathway (PPP)—that is, glucose-6-phosphate dehydrogenase
(G6PDH)—was evaluated. First-strand complementary DNA was
synthesized from 3 L of the total RNA using random hexamer
and Superscript II reverse transcriptase (Life Technologies). One
microliter of the reverse transcription reaction mixture was ampli-
fied with primers specific for G6PDH, and glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) as an internal control in the total
volume of 50 L. Linearity of the PCR was tested by amplification
cycles between 25 and 30. Primers used in PCR were as follows:
FIGURE 1. (A) Two-dimensional gel electrophoresis map of human liver tumor tissue demonstrates numerous protein spots. (B)
Proteome analysis enables grouping of tumors (normal, HCC, and cholangiocarcinoma groups) as seen on distance tree mapping
of protein expression profiles. However, protein expression pattern of intermediate phenotype of HCC group (patient 7) is close to
cholangiocarcinoma group.
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● G6PDH-sense, 5-ACCTGGCCAAGAAGAAGATC-3,
● G6PDH-antisense, 5-TAGGAGGCTGCATCATCGTA-3,
● GAPDH-sense, 5-ACCAC AGTCC ATGCC ATCAC-3,
● GAPDH-antisense, 5-TCCAC CACCC TGTTG CTGTA-3.
RESULTS
Immunohistochemistry
Immunoreactivity for Glut 1 was positive in all cholan-
giocarcinomas but was negative in all HCCs except one
(Table 1). In contrast, HK II was positive in HCCs but was
negative in 6 of 7 cholangiocarcinomas (Figs. 2 and 3).
CK-19 was positive only in the HCC, which had positive
reactions for both Glut 1 and HK II. This is consistent with
the intermediate phenotype of HCC (Fig. 4).
HK I was weakly positive in only one HCC, and HK-III was
weakly positive in one HCC and 2 cholangiocarcinomas.
Protein Expression Profiles
A total of 331 protein spots that had a P value of 0.05
were selected for identification. Thirteen proteins in-
volved in the metabolism of carbohydrates were chosen
from this total for comparison and were classified as
shown in Table 2.
PPP. The expression of 6-phosphogluconolactonase,
the second step enzyme in the PPP, was markedly in-
creased in group B (Fig. 5). Although G6PD, the first
step-regulating enzyme, was not identified on proteome
analysis, mRNA expression on the RT–PCR significantly
increased as the 6-phosphogluconolactonase protein ex-
pression pattern (Fig. 6).
Tricarboxylic Acid (TCA) Cycle. Six enzymes of 8 suc-
cessive reaction steps in the TCA cycle were differentially
expressed. Isocitrate dehydrogenase (3rd-step reaction en-
zyme) and -succinyl CoA synthetase (5th-step reaction
enzyme) were increased, whereas -ketoglutarate dehydro-
genase (4th-step reaction enzyme), succinate dehydroge-
nase (6th-step reaction enzyme), and fumarase (7th-step
reaction enzyme) were decreased in both groups, more
significantly in group B. Pyruvate carboxylase involving in
FIGURE 2. Nodular HCC (Edmondson grade II–III) in right lobe
of liver, inferior segment, shows increased 18F-FDG uptake on
PET scan (patient 3). Immunohistochemical staining shows a
negative reaction for Glut 1 but a positive reaction for HK II
(400).
FIGURE 3. Mass-forming cholangiocarcinoma in right lobe of
liver, inferior segment, shows intense 18F-FDG uptake (patient
10). Pathologically, tumor shows a strong positive reaction for
Glut 1 along cell membrane but a negative reaction for HK II
(400).
TABLE 1




(y) Sex Pathology SUV Glut 1 HK I HK II HK III
1 40 M HCC, G II–III 3.3   	 
2 54 M HCC, G III 3.9   	 
3 54 M HCC, G II–III 5.6  Weak 	 Weak
4 50 M HCC, G III, HB cirrhosis 3.2   	 
5 58 F HCC, G II–III, HB cirrhosis 7.3   	 
6 63 F HCC, G III, HB cirrhosis 3.8   	 
7 53 F Intermediate HCC, HB cirrhosis 10.0 	  	 
8 41 F Cholangiocarcinoma, MD 13.4 	   
9 48 F Cholangiocarcinoma, MD 9.1 	   
10 52 M Cholangiocarcinoma, MD 13.5 	   Weak
11 47 F Cholangiocarcinoma, PD 8.7 	   
12 73 M Cholangiocarcinoma, MD 6.2 	  Weak 
13 75 M Cholangiocarcinoma, PD 12.8 	   
14 54 F Cholangiocarcinoma, PD 17.4 	   Weak
G  grade; HB  hepatitis B; MD  moderately differentiated; PD  poorly differentiated.
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anaplerotic reaction increased in group A but decreased in
group B.
Gluconeogenesis. Glyoxalate reductase/hydroxypyruvate
reductase was decreased in group B, and phosphoenolpyru-
vate carboxykinase (PEPCK) was decreased in both groups,
but was more pronounced in group A.
Others. Pyruvate kinase, mannosephosphate isomerase,
citrate lyase, and ketohexokinase decreased in both groups.
Glutathione peroxidase (GPO), which is essential in the
normal detoxification of H2O2, was increased in both
groups. This increase was higher in group B (Fig. 5).
Glut 1 and HK proteins could not be identified on pro-
teome analysis, possibly due to technical difficulties en-
countered during the extraction of membranous proteins
(14).
DISCUSSION
Hepatocyte origin HCCs and bile duct origin cholangio-
carcinomas are the major primary hepatic carcinomas. Al-
though both high-grade HCCs and intrahepatic mass-form-
ing cholangiocarcinomas showed high rates of glycolysis—
that is, increased 18F-FDG uptake on PET scans—our
results demonstrated that the mechanisms involved in glu-
cose uptake and glycolytic metabolism appear to be differ-
ent from each other.
FIGURE 4. Mass with intense 18F-FDG
uptake as seen in Figures 2 and 3 shows a
positive reaction for both Glut 1 and HK II
and, additionally, the biliary marker CK-19
(patient 7) (400). Morphologically, lesion
is classified as an HCC; however, biologi-
cally, it has both HCC and cholangiocarci-
noma phenotypes.
TABLE 2




FunctionGroup A Group B
PPP
6-Phosphogluconolactonase NP_036220 1.2 2.5 6-Phosphogluconolactone36-phosphogluconate
TCA cycle
Pyruvate carboxylase P 11498 2.0 0.3 Anaplerotic reaction, pyruvate3oxaloacetate
Isocitrate dehydrogenase NP_005521 2.6 3.5 TCA cycle (3rd step), isocitrate3-ketoglutarate
-Ketoglutarate dehydrogenase AAH 26320 0.7 0.1 TCA cycle (4th step), -ketoglutarate3succinyl CoA
-Succinyl CoA synthetase AAP 97189 1.8 2.5 TCA cycle (5th step), succinyl CoA3succinate
Succinate dehydrogenase P31040 0.4 0.2 TCA cycle (6th step), succinate3fumarate
Fumarase NP_000134 0.7 0.5 TCA cycle (7th step), fumarate3malate
Gluconeogenesis
Phosphoenolpyruvate carboxykinase A45746 0.1 0.4 Phosphoenolpyruvate3oxaloacetate
Glyoxylate reductase NP_036335 1.0 0.2 Serine3glucose
Others
Mannosephosphate isomerase NP_002426 1.3 2.4 Mannose-6-phosphate3fructose-6-phosphate
Pyruvate kinase NP_870986 0.4 0.2 Phosphoenolpyruvate3pyruvate
Citrate lyase AAL84703 0.7 0.3 Citrate3acetyl CoA
Ketohexokinase CAA55346 0.7 0.1 Fructose3fructose-1-phosphate
PPP  pentose phosphate pathway; TCA  tricarboxylic acid; CoA  coenzyme A.
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Although most malignant cells highly express glucose
transporters, especially Glut 1 (6,15), it is not increased in
HCCs (7), as was seen in our study. The exact mechanisms
have not been fully evaluated, but previous reports have
revealed that the growth of HCCs is glutamine dependent
(16,17), and fatty acids are the major energy source in HCC
cells (18). These findings might be possible explanations for
the low incidence of Glut 1 expression and lower 18F-FDG
uptake in HCCs compared with cholangiocarcinomas.
In addition to Glut 1, HKs—the first rate-limiting en-
zymes of the glycolytic pathway—also play a pivotal role in
18F-FDG uptake and glycolytic pathways in malignant cells.
Among the 4 hexokinase isozymes in mammalian tissues
(HK I–IV), HK II is markedly increased in rapidly growing,
highly malignant tumors, including HCCs (19,20). Addi-
tionally, an isozyme shift from type IV (glucokinase) to HK
II has been observed in HCCs (21,22). However, most of the
cholangiocarcinoma tissues did not demonstrate increased
expression of HK II despite high 18F-FDG uptake. The
mechanisms of low expression of HK II in cholangiocarci-
noma were not investigated, but previous data demonstrated
that glucose-6-phosphate production depends more on the
phosphorylating enzyme activity of HK II than on the
protein expression level (23) and hexokinase is inhibited by
the increased concentration of intracellular glucose-6-phos-
phate, which suggests that 18F-FDG uptake does not always
parallel the HK protein expression level. However, in con-
ditions in which carbohydrates are limiting, as is seen in
HCCs (24), it is important to have an increased amount of
HK II protein, especially the mitochondrial bond form for
efficient glucose use in cancer cells. In fact, mitochondrial-
bound hexokinase accounts for as much as 70% of the total
cellular hexokinase in hepatoma cells, whereas the amount
found on the mitochondria in normal liver cells is negligible
(25). HK II bound to porins on the outer mitochondrial
membrane prevents apoptosis via Bax-induced inhibition of
cytochrome c release (26), Bax conformation change, and
BID cleavage in association with activated serine/threonine
kinase Akt/PKB (Akt) (27,28).
Glucose-6-phosphate produced by HK II can be used for
lactate production, glycogen synthesis, the PPP for lipid or
nucleotide synthesis, and also reduced nicotinamide adenine
dinucleotide phosphate (NADPH) generation to maintain
the redox state of the tumor cells under oxidative stress.
However, use of glucose-6-phosphate for oxidative phos-
phorylation via the TCA cycle is relatively lower than for
glycolysis or the PPPs as described previously (29–31).
In our study, both tumors showed an increase in the
expression of the second-step enzyme, 6-phosphoglucono-
lactonase, in terms of the PPP. The increase was greater in
group B. Although the first-step enzyme, G6PDH, was not
identified by proteome analysis—probably due to failure in
protein solubilization during the IEF step (14)—mRNA
expression was markedly increased in group B on RT–PCR.
These findings may support the fact that the PPP plays an
important role in cancer cell survival in cholangiocarcino-
mas or intermediate-phenotype HCCs. NADPH generated
by enhanced pentose phosphate shunt produces the reduced
form glutathione (GSH) from the oxidized form (GSSH);
therefore, it further activates 6-phosphogluconolactonase
activity (32). Moreover, glutathione peroxidase, which ren-
ders the cells resistant to H2O2, was overexpressed in our
study, particularly in group B. This appears to be an addi-
tional cellular protective mechanism against oxidative
stress.
The enzyme expression pattern involved in the TCA
cycle was variable. Fluctuation in the concentration of
key metabolites such as glutamine and glutamate, which
reflect the cellular balance between adenosine triphos-
phate production and consumption, could have caused
these enzyme expression variations. The clinical impli-
cations of metabolic regulations in the TCA cycle were
not fully investigated in these tumors. Further studies are
required.
FIGURE 6. mRNA expression of glucose-6-phosphate dehy-
drogenase (G6PDH) is markedly increased in intermediate-
phenotype HCC and cholangiocarcinomas (Cholangio) com-
pared with normal and HCC.
FIGURE 5. Protein expression level of glutathione peroxidase
(GPO) and especially 6-phosphogluconolactonase (6-PGL) is
increased in both HCC and cholangiocarcinomas, more in chol-
angiocarcinoma group. (Group A includes HCCs; group B in-
cludes intermediate phenotype of HCC and cholangiocarcino-
mas.)
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Gluconeogenic enzymes such PEPCK were diminished in
both groups, which is concordant with a previous report
(33), and activation of Akt is known to be sufficient to
repress the glucocorticoid and cyclic adenosine monophos-
phate–stimulated increase in PEPCK gene transcription
(34).
An intriguing finding in our study was that the protein
expression pattern in the intermediate phenotype of HCCs
was quite close to that of cholangiocarcinomas. Detailed
molecular and biologic analysis in this particular type of
cancer is required for a better understanding of the tumor
characteristics and behaviors.
CONCLUSION
HCCs have different glucose-regulating mechanisms
and enzyme expression pattern than those of cholangio-
carcinomas, even though both tumors show similarity in
the enhanced glucose uptake pattern on PET scans. Fur-
ther studies are required with regard to the energy me-
tabolism and 18F-FDG uptake patterns in association with
various oncogenic alterations, because the tumor-sup-
pressor genes p53, H-ras, HIF-, c-myc, and Akt regulate
glucose use in multiple steps of the glycolytic pathways
(35).
ACKNOWLEDGMENTS
This study was supported by the Brain Korea 21 Project
in Medical Science, a faculty research grant of Yonsei
University College of Medicine for 2003 (no. 6-2003-1033),
the National Core Research Center for Nanomedical Tech-
nology (grant R15-2004-024-02002-0), and a nuclear re-
search and development project, Ministry of Science and
Technology, Korea
REFERENCES
1. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET
imaging for cancer patient management and oncologic drug development. Clin
Cancer Res. 2005;11:2785–2808.
2. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314.
3. Ho CL, Yu CH, Yeung DWC. 11C-Acetate PET imaging in hepatocellular
harcinoma and other liver masses. J Nucl Med. 2003;44:213–222.
4. Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in
intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1467–
1472.
5. Lee JD, Yun M, Lee JM, et al. Analysis of gene expression profiles of hepato-
cellular carcinomas with regard to F-18-FDG uptake pattern on positron emission
tomography. Eur J Nucl Med Mol Imaging. 2004;31:1621–1630.
6. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in
dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression
in pancreatic cancer. J Nucl Med. 2002;43:173–180.
7. Roh MS, Jeong JS, Kim YH, Kim MC, Hong SH. Diagnostic utility of GLUT 1
in the differential diagnosis of liver carcinomas. Hepatogastroenterology. 2004;
51:1315–1318.
8. Zimmerman RL, Fogt F, Burke M, Murakata LA. Assessment of Glut-1 expres-
sion in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Oncol Rep. 2002;9:689–692.
9. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells:
isolation, sequence, and activity of the promotor type II hexokinase. J Biol Chem.
1995;270:16918–16925.
10. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepa-
tocyte-cholangiocyte) phenotype. J Hepatol. 2004;40:298–304.
11. Bradford NM. A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem.
1976;72:248–254.
12. Oakley BR, Kirsch DR, Morris NR. A simplified ultrasensitive silver stain for
detecting proteins in polyacrylamide gels. Anal Biochem. 1980;105:361–363.
13. Shevchenko A, Wilm M. Vorm O, Mann M. Mass spectrometric sequencing of
proteins in silver-stained polyacrylamide gels. Anal Chem. 1996;68:850–858.
14. Santoni V, Molloy M, Rabilloud T. Membrane proteins and proteomics: Un
amour impossible? Electrophoresis. 2000;21:1054–1070.
15. Larson SM. Positron emission tomography-based molecular imaging in human
cancer: exploring the link between hypoxia and accelerating glucose metabolism.
Clin Cancer Res. 2004;10:2203–2204.
16. Wong MS, Raab RM, Rigoutsos I, Stephanopoulos GN, Kelleher JK. Metabolic
and transcriptional patterns accompanying glutamine depletion and repletion in
mouse hepatoma cells: a model for physiological regulatory networks. Physiol
Genomics. 2004;16:247–255.
17. Bode BP, Fuchs BC, Hurley BP, et al. Molecular and functional analysis of
glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol
Gastrointest Liver Physiol. 2002;283:G1062–G1073.
18. Hansson PK, Asztely AK, Clapham JC, Schreyer SA. Glucose and fatty acid
metabolism in McA-RH7777 hepatoma cells vs. rat primary hepatocytes: respon-
siveness to nutrient availability. Biochim Biophys Acta. 2004;1684:54–62.
19. Wilson JE. Isozymes of mammalian hexokinases: structure, subcellular localiza-
tion and metabolic function. J Exp Biol. 2003;206:2049–2057.
20. Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer: evidence
that methylation events play a role in activating type II hexokinase gene expres-
sion. J Biol Chem. 2003;278:15333–15340.
21. Klimek F, Bannasch P. Isozyme shift from glucokinase to hexokinase is not an
early but a late event in hepatocarcinogenesis. Carcinogenesis. 1993;14:1857–
1861.
22. Rencurel F, Munose-Alonso MJ, Girard J, Leturque A. An unusual high Km
hexokinase is expressed in the mhAT3F hepatoma cell line. J Biol Chem.
1998;273:26187–26193.
23. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neuman RD. Glut-1 and hexokinase
expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and
T47D cells in culture. Cancer Res. 1999;59:4709–4714.
24. Rempel A, Mathupala SP, Pedersen PL. Glucose catabolism in cancer cells:
regulation of the type II hexokinase promoter by glucose and cyclic AMP. FEBS
Lett. 1996;385:233–237.
25. Parry DM, Pedersen PL. Intracellular localization and properties of particulate
hexokinase in the Novikoff ascites tumor: evidence for an outer mitochondrial
membrane location. J Biol Chem. 1983;258:10904–10912.
26. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II
inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2003;
277:7610–7618.
27. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB.
Akt-directed glucose metabolism can prevent Bax conformation change and
promote growth factor-independent survival. Mol Cell Biol. 2003;23:7315–7328.
28. Majewski N, Nogueira V, Robery RB, Hay N. Akt inhibits apoptosis downstream
of BID cleavage via a glucose-dependent mechanism involving mitochondrial
hexokinases. Mol Cell Biol. 2004;24:730–740.
29. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in
cancer cells. Cancer Res. 2004;64:3892–3899.
30. Hacker HJ, Sreingerg P, Toshkov I, Oesch F, Bannasch P. Persistence of
cholangiocellular and hepatocellular lesions observed in rats fed a choline-
deficient/DL-ethionine-supplemented diet. Carcinogenesis. 1992;13:271–276.
31. Frederiks WM, Bosch KS, De Jong JSSG, Van Noorden CJF. Post-translational
regulation of glucose-6-phosphate dehydrogenase activity in (pre)neoplastic le-
sions in the rat liver. J Histochem Cytochem. 2003;51:105–112.
32. Fratelli M, Demol H, Puype M, et al. Identification by redox proteomics of
glutathionylated proteins in oxidative-stressed human T lymphocytes. Proc Natl
Acad Sci USA. 2002;99:3505–3510.
33. Hammond KD, Balinsky D. Activities of key gluconeogenic enzymes and gly-
cogen synthase in rat and human livers, hepatomas, and hepatoma cell cultures.
Cancer Res. 1978;38:1317–1322.
34. Liao J, Barthel A, Nakatani K, Roth RA. Activation of protein kinase B/Akt is
sufficient to repress the glucocorticoid and cAMP induction of the phosphoenol-
pyruvate carboxykinase gene. J Biol Chem. 1998;273:27320–27324.
35. Dang CV, Semenza GL. Oncogenic alteration of metabolism. Trends Biochem
Sci. 1999;24:68–72.
GLUCOSE UPTAKE AND GLYCOLYTIC MECHANISMS • Lee et al. 1759
by Yonsei University - Medical Library on July 2, 2014. For personal use only. jnm.snmjournals.org Downloaded from 
